Screener
Mineralys Therapeutics, Inc. MLYS Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Mineralys Therapeutics, Inc.’s reported figures.
The source filing: Mineralys Therapeutics, Inc.’s 10-K, filed March 12, 2026. Open the filing →
- Filed
- Mar 12, 2026, 5:19 PM EDT
- Fiscal year
- FY2025
- Accession
- 0001933414-26-000056
FAQ
- What is Mineralys Therapeutics, Inc.'s free cash flow?
- Mineralys Therapeutics, Inc. (MLYS) reported free cash flow of -$37.9M in Q4 2025.
- How has Mineralys Therapeutics, Inc.'s free cash flow changed year-over-year?
- Mineralys Therapeutics, Inc.'s free cash flow increased by 43.3% year-over-year, from -$66.84M to -$37.9M.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s free cash flow?
- Over 2 years (2023 to 2025), Mineralys Therapeutics, Inc.'s free cash flow has grown at a 32.5% compound annual growth rate (CAGR), from -$81.17M to -$142.43M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.
Ask your AI about Mineralys Therapeutics, Inc.'s free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude